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Recovery of cortical phospholipidosis and necrosis after acute
gentamicin loading in rats. The recovery from gentamicin-induced
phospholipidosis in the rat kidney cortex was characterized both
morphologically and biochemically after a single 12-hr drug infusion.
Total dosages administered were 10, 60, or 140 mg/kg, achieving
constant serum concentrations of 3, Ii, and 27 g/m1, respectively. At
the end of the 12-hr infusion, the cortical drug concentrations cor-
responding to the three dosages were 124, 450, and 993 sg/g of wet
tissue. At the low dose (10 mg/kg), myeloid bodies were seen inside
lysosomes of proximal tubular cells, along with a modest decrease of
lysosomal sphingomyelinase activity. The cortical drug level declined
steadily following first-order kinetics along with a disappearance of
myeloid bodies and return of sphingomyelinase activity to control
levels. At the high dose (140 mg/kg), we observed a sustained loss of
sphingomyelinase activity (37% of controls), a subsequent increase of
phospholipid concentration in the kidney cortex (up to 117% of controls
2 days after) and a prominent accumulation of myeloid bodies inside the
lysosomes of proximal tubular cells (up to 4% of cell volume). Tubular
regeneration and interstitial infiltration became detectable by histology
and the increase of DNA synthesis as from day I, along with an
apparent reduction of the phospholipidosis at days 3 and 4. Drug
cortical concentrations showed a sharp decline 2 days after infusion. An
intermediate behavior was observed at 60 mg/kg. it is concluded that
the proximal tubular cells behave in a fundamentally different way after
gentamicin loading with low and high doses. At the low dose there is a
regression of the drug-induced changes in the absence of any sign of
necrosis-regeneration. Above a threshold in cortical drug concentration
there is further development of the alterations leading to cell death-
regeneration.
Rétablissement après Ia phospholipidose et Ia nécrose corticales
provoquees par Ia surcharge aigue en gentamicine chez le rat. Le
rbtablissement de Ia phospholipidose du cortex renal de rat induite par
Ia gentamicine a bib caractbrisbe morphologiquement et biochimique-
ment apres une perfusion médicamenteuse unique de 12 hr. Les doses
totales administrbes btaient de 10, 60, ou 140 mg/kg, donnant des
concentrations sériques constantes de 3, 11, et 27 .mg/ml, respective-
ment. A Ia fin de Ia perfusion de 12 hr, les concentrations corticales de
gentamicine correspondant aux trois doses btaient de 124, 450, et 993
zg/g de tissu humide. A Ia dose faible (10 mg/kg) des corps mybloides
btaient visibles dans les lysosomes des cellules tubulaires proxirnales,
avec une faible diminution de l'activitb de Ia sphingomyblinase
lysosomiale. La concentration corticale du mbdicament a diminué
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progressivement scion une cinbtique de premier ordre en mbme temps
que disparaissaient les corps myeloides et que l'activitb de Ia
sphingomyelinase revenait aux riiveaux contrôles. A Ia forte dose (140
mg/kg) nous avons observe une perte prolongbe de l'activité de Ia
sphingomyélinase (37% des contrOles), une augmentation de Ia concen-
tration en phospholipides dans Ic cortex renal jusqu'à 117% des
contrôies 2 jours plus lard) et une accumulation importante de corps
myeloides dans les lysosomes des cellules tubulaires proximales
(jusqu'h 4% du volume cellulaire). La regeneration tubulaire et
l'infiltration interstitielle sont devenues dbtectables en histologic ci par
mesure de Ia synthese de DNA des Ic jour I. line reduction apparente
de Ia phospholipidose a bib observbe aux jours 3 et 4. Les concentra-
tions corticales du mbdicament prbsentaient une chute prononcee 2
jours aprbs Ia perfusion. Un comportement intermédiaire btait observée
pour 60 mg/kg. On conclut que les cellules tubulaires proximales se
comportent dune facon fondamentalement diffbrente après surcharge
en gentamicine a des faibles ou des fortes doses. A faible dose, il existe
une regression des changements induits par Ic mbdicament en l'absence
de tout signe de necrose-regeneration. Au-dessus d'un seuil de concen-
tration corticale de médicament, ii y a un developpement constant des
lesions conduisant a une mort cellulaire suivie de regeneration
tubulaire.
Gentamicin toxicity in the kidney cortex of humans and
animals includes an early, conspicuous lysosornal phospholi-
pidosis in proximal tubular cells and a subsequent necrosis of
this part of the nephron [1—10]. Both alterations are probably
related to the accumulation of gentamicin in proximal tubular
cells [11—15] where the drug is predominantly concentrated
within lysosomes [12, 16—18]. The mechanism of the
phospholipidosis is now fairly well understood [10, 19—21], and
comparative studies with several aminoglycosides [22—24] have
demonstrated a correlation between phospholipidosis and
necrosis. In the aforementioned studies, the animals were
treated with repeated injections during several days. While this
approach mimics the clinical use of aminoglycosides, it menges
primary lesions (phospholipidosis, necroses) with regenerative
processes. Regeneration of kidney cortex during therapy has
indeed been reported in animals treated at both high [25, 26] and
low doses [23, 24, 27]. We have therefore developed a protocol
in which gentamicin was administered over a 12-hr period only,
yet allowing a substantial and fast accumulation of the drug in
the kidney cortex. This procedure should allow us to observe
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more effectively the renal cortical kinetics of drug elimination
and the recovery of the phospholipidosis and focal necroses
induced by gentamicin at different tissue drug concentrations.
Methods
Animals and treatment
Female Wistar rats weighing 230 to 250 g were used through-
out the experiment. The animals were fed with a standard rat
chow (no. A 04, U.A.R., Epinay s/Orge, France) and given tap
water ad libitum. During the infusion period, as well as during
the subsequent days, the animals had free access to both water
and food. Under light ether anesthesia a polyethylene catheter
(PE 50, Intramedic, Clay Adams, Parsipanny, New Jersey,
USA) filled with saline was secured into the right communis
jugular vein and the other end was guided subcutaneously until
it emerged through a hole made in the skin of the neck. A slight
tension was exerted on the cannula by means of a light
counterweight to prevent the animal from damaging the inserted
catheter. This made any restraining device unnecessary. One
hour after full recovery from anesthesia, the animals received a
loading dose of gentamicin to instantaneously achieve the
desired serum level. Then the cannulae were connected to
50-mi plastic syringes (Perfusor®, B. Braun, Federal Republic
of Germany) containing the appropriate gentamicin solution and
mounted in a continuous flow infusion pump (series 2200,
Harvard dual syringe high capacity infusion/withdrawal pump,
Harvard Apparatus Company, Inc., Massachusetts, USA) for
12 hr. The rate of infusion was 19.1 l/min. We divided the
animals in three groups, corresponding to serum concentrations
of about 2 g/ml (similar to human through level), 11 g/ml
(similar to human peak level), and 27 ig/ml. The loading and
infusion doses necessary to obtain these serum concentrations
were calculated from the serum half-life, elimination constant,
and distribution volume of gentamicin in rats. These parameters
were determined in preliminary experiments and were not
different at low and high doses. The total doses administered in
the present experiments (over 12 hr) were 10, 60, and 140
mg/kg, which will be referred to henceforth as low, medium and
high.
To check for the actual gentamicin serum levels, blood
samples were drawn from the tip of the tail 4 and 10 hr after
starting the infusion. Control animals were infused with saline
only. For the in vivo measurement of DNA synthesis in kidney
cortex, all animals received 1 hr before sacrifice, an
intraperitoneal injection of 200 sCi of [methyl-3H1-thymidine
(43 Ci/mmole) diluted in 0.5 ml 0.9% NaCl.
Tissue sampling
Groups of four rats for each dose and four control animals
were killed 2 hr after the end of the infusion (this time will be
referred henceforth as day 0) and on each of the next 4 days.
For the low dose, an additional group was killed 6 days after the
infusion for morphological studies only. After decapitation and
bleeding, the kidneys were quickly removed and bisected. A 5
x 5 mm sample was immediately dissected from the cortex of
the right kidney, cut into small blocks of 1 mm3 in a drop of
fixative (2% glutaraldehyde, 1% sucrose, 0.1 M cacodylate
buffer, pH 7.4) and kept in this solution for 24 hr before further
processing for electron microscopy. A transversal slice (2-mm
thick) of the left kidney was fixed in Dubosq-Brazil for light
microscopy and a second slice in Bouin's fixative for
hi stoautoradiographic studies. For determination of gentamicin
concentration, 100-mg samples of cortical tissue were taken
from both kidneys of each animal, immediately weighed,
wrapped in Parafilm® to minimize water loss and frozen at
—20°C. The remaining cortical tissue was quickly frozen at
— 80°C in small tubes and kept at —20°C until processing for
biochemical assays and measurement of DNA specific
radioactivity.
Biochemical analysis
The measurement of DNA specific radioactivity was per-
formed as previously described [27] on highly purified DNA
obtained from cortical tissue of one kidney from each animal.
In preliminary experiments, however, left and right kidneys
were processed in parallel to check for the consistency of the
response within the same animal; no major difference was
observed between both kidneys. Sphingomyelinase activity
(hydrolysis of [N-methyl- '4C1-sphingomyelin; EC 3.1.4.12), to-
tal phospholipids, and proteins were assayed on the other
kidney from each animal by published methods [10].
Gentamicin concentration was measured in both kidneys by
radioimmunoassay after repetitious homogenization-extraction
and deproteinization with trichioroacetic acid as previously
reported [281.
Morphological analysis
Light microscopy and histoautoradiography. Samples were
embedded in paraffin; sections (approximately 6 m) were
stained with hematoxylin and eosin (H & E), or (H & E)
combined with the periodic acid-Schiff stain procedure. For
histoautoradiography, unstained sections were coated with
NTB Kodak® emulsion. After drying, the specimens were
stored in the darkness and at 4°C for 14 or 28 days, and
processed as previously described [27]. In addition to paraffin
sections, samples were also examined by the "plastic section"
technique (see below).
Electron microscopy and morphometry. Samples were post-
fixed with 2% 0504 in veronal acetate buffer, pH 7.4, block
stained in 2% uranyl-acetate, dehydrated in acetone, and em-
bedded in Epon 812. From each rat, two blocks were taken at
random. A first survey was performed on l-m thick sections
stained with toluidine blue ("plastic sections"). A zone contain-
ing proximal tubular profiles was randomly picked out and
trimmed for ultra-thin sectioning. Ultra-thin sections (approxi-
mately, 60 nm) were cut with a diamond knife and poststained
with lead citrate. From each ultra-thin section, six or seven
micrographs were taken with an electron microscope (model
EM, Zeiss, Oberkochen, Federal Republic of Germany) at a
x 3,000 magnification. The micrographs were enlarged to obtain
prints at a final magnification of exactly x 10,000 (scanned
surface of proximal tubular profiles varied between 1,591 and
2,406 Is2 for each animal). Morphometry of myeloid bodies,
lysosomes, and electron-lucent vacuoles were performed by the
point counting method as described by Weibel [29, 30] using
two lattices of four and nine equidistant points per square
micron of tissue, respectively. This method allows the calcula-
tion of the aggregated volume of the structures studied, as a
percent of the total cell volume (including in the present case
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nuclei and brush border), but gives no information on their size
distribution,
Statistical analysis. Non-parametric statistics (Mann
Whitney-U test) 3 I] were used to analyze the biochemical and
morphometrical data.
Materials. Rats were obtained from lifa-Credo (L'Arbresle,
France). Gentamicin was supplied as the sulfate salt used in
clinical practice (Schering Corp., Kenilworth, New Jersey,
USA). The kit for gentamicin radioimmunoassay was pur-
chased from Clinical Assays, Division of Travenol Laborato-
ries, Inc., Cambridge, Massachusetts, USA. [N-methyl-'4C]-
sphingomyelin (60 mCi/mmole) and [methyl-3H]-thymidine (43
Ci/mmole) both came from Amersham International
(Amersham, United Kingdom). The radiolabelled thymidine
was 99% pure, as stated by the supplier and the stock solution
was kept sterile at 4°C and used within 2 to 3 weeks after
receipt. DNA (from herring sperm, type VII) and
sphingomyelin (from bovine brain) came from Sigma Chemical
Co. (St. Louis, Missouri, USA). Other reagents were of analyti-
cal grade.
Results
Gentamicin concentration in serum and kidney cortex
The serum levels, measured at hours 4 and 10 of the infusion
in each animal did not markedly differ from each other (mean
difference, 16 7%; N = 120). Average values were 2.6 1.3,
10.9 3.6, and 26.7 5.3 g/ml (±sD) for the animals
receiving 10 mg/kg (low dose); 60 mg/kg (medium dose) and 140
mg/kg (high dose), respectively. Figure 1 shows the cortical
concentrations observed 2 hr after the end of the infusion and
during the next 4 days. For the low dose, tissue concentration
declined following a first order kinetic with a half-life of 118 hr.
In contrast, in the two higher doses, the kinetics of elimination
were not first order. True half lives could not be calculated.
Biochemical studies
Phospholipidosis. Figure 2 shows that sphingomyelinase ac-
tivity, measured at day 0 (2 hr after the end of the perfusion),
was decreased according to the dosage administered. At the low
and medium doses, the enzyme activity returned to normal
values within a period of 2 to 3 days following the treatment. At
the high dose, recovery was also observed but was not yet
complete at day 4. The total content of phospholipids in the
cortex after gentamicin administration at 10 mg/kg showed no
significant change compared to controls at day 0 and during the
following 4 days. At 60 mg/kg, a transient increase was ob-
served (up to 108% of controls at day 1) with a return to normal
values at day 3. The dosage of 140 mg/kg induced a significant
rise in phospholipid concentration with a peak appearing 2 days
after the gentamicin administration (up to 117% of controls).
Despite the decrease occurring thereafter, phospholipid content
still remained significantly higher at day 4, as compared to
control values.
Total DNA synthesis. Figure 3 shows the specific radioactiv-
ity of kidney cortex DNA. In the animals treated with 10 mg/kg
we observed that the thymidine incorporation was only half of
that in controls immediately after the end of the perfusion (P <
0.05), but returned to control values thereafter. In contrast, in
the animals treated with the highest dose, a striking and
0 1 2 3 4
Time interval, days
Fig. 1. Renalcortical gentarnicin concentration 2 hr after i/ic end of the
infusion (day 0) and during the subsequent 4 days. The animals were
infused during 12 hr with a total dose of 10 (I), 60 (A), and 140 (U)
mg/kg. Each symbol represents the value for one treated rat (mean of
the cortical concentrations in both kidneys). The lines connect the
medians of each group of four treated animals.
significant increase of 3H1-thymidine incorporation occurred at
days I and 2 which decreased thereafter but remained signifi-
cantly higher as compared to controls. The medium dose
induced some increased incorporation also, but the difference
with control animals was significant only at day 3. The tissue
acid-soluble radioactivity (that is, radioactivity associated with
free thymidine or its low molecular weight derivatives) was
measured in animals from both control and the high dose group.
No significant difference was observed, indicating that the
treatment did not modify the distribution and the availability of
the labelled precursor.
Morphological examination
Light microscopy and histonutoradiography. Paraffin sec-
tions revealed consistent alterations in the proximal tubules
only at the high dose of gentamicin. These lesions exhibited
degeneration and necrosis signs, that is, pycnosis, apoptosis,
zones of tubuli with a naked basal membrane, and accumulation
of nuclei and cell debris in the lumen. Plastic sections obtained
from animals treated at the low and medium doses showed a
marked enlargement of the lysosomes of the proximal tubules,
filled with an heterogenous, osmiophilic material. These altera-
tions were widespread among proximal tubules.
Regeneration was also observed in the treated animals at the
medium and high doses, and was particularly prominent on
days 3 and 4. Proximal tubules contained, next to differentiated
cells, round epithelial cells with an ill-developed brush border,
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0 1 2 3 4days
140 mg/kg (.) P<0.05
60 mg/kg (i) P<0.05
10 mg/kg (.) P<0.05
P<0.05
P<0.05
NS
P<005
P<0,05
NS
P<0.05
NS
NS
P.:0.05
NS
NS
Fig. 2. Activity of lysosomal sphingomyelinase (sphingomyelin
phosphodiesterase EC 3.1 .4.12) in the cortex 2 hr after infusion with
gentamicin (day 0) and daring the subsequent 4 days. The animals were
treated with 10 (•), 60 (A), and 140 () mg/kg of gentamicin infused
during 12 hr. Each symbol represents the value for one treated rat,
expressed in percent of the pooled value for controls (N = 16) infused
with saline. The variation of these controls is shown by the stripped
area which spans between the lowest and highest values. The lines
connect the medians of each group of four treated animals. Statistical
analysis (groups of treated animals which show a significant difference
compared to pooled controls values) is presented at the top of the
figure.
a basophilic cytoplasma and an enlarged nucleus with a promi-
nent nucleolus (Fig. 4A). Mitotic figures were observed in these
tubules. Peritubular infiltration by mononuclear cells (most of
them lymphocytes) was observed in the animals treated at the
medium and high doses. This infiltration was, however, focal
and its intensity varied among individual animals.
Histoautoradiography showed labelled nuclei throughout the
cortex, and their abundance was related to the rate of [3H1-
thymidine incorporation into DNA (see above). The labelling
was especially prominent in proximal tubules and interstitium.
In two animals treated at the high dose, the distribution for 500
labelled nuclei was 42% in proximal tubules, 45% in
interstitium, 11% in distal tubules, and 2% in glomeruli. For
tubular cells, clusters of labelled nuclei were seen in regenerat-
ing tubules (Fig. 4B), but labelled nuclei were also observed in
seemingly normal tubules (Fig. 4C). For the interstitium, the
presence of the grains did not allow unambiguous assignment to
a particular cell type. Many cells with an elongated shape
(fibroblasts or endothelial cells?) were observed throughout the
0 1, 2 3 4days
140 mg/kg (.) NS P<0.05 P<0.05 P<0.05 P<0.05
60 mg/kg (A) NS NS NS P<0.05 NS
10 mg/kg (.) P<0.05 NS NS NS NS
Fig. 3. Incorporation of [3HJ-thymidine into kidney cortex DNA 2 hr
after the end of the infusion with gentamicin and during the next 4 days.
The animals were treated with 10 (•), 60 (A), and 140 (•) mg/kg.
[3H1-thymidine (200 Ci) was injected 1 hr before sacrifice. Each
symbol represents [3H1-thymidine incorporated in the cortical DNA of
one treated animal and expressed in percent of all pooled control values(N = 16) from animals infused with saline. The variation of these
controls is shown by the stripped area which spans between the lowest
and highest values. The lines connect the medians of the groups of
treated rats. Statistical analysis (groups of treated animals which show
a significant difference compared to controls) is presented at the top of
the figure.
interstitium (Fig. 4D). in addition, occasional clusters of label-
led cells in zones of lymphocytic infiltration were also seen (Fig.
4E).
Electron microscopy and inorphometry. In all animals exam-
ined immediately after the infusion (day 0), proximal tubular
cells showed osmiophilic, lainellar structures (myeloid bodies)
in the lysosomes. The abundance of this material and its fate
during the observation period, however, varied depending on
the dosage. Quantitative data are shown in Table 1, along with
morphometry of lysosomes. At the low doses, myeloid bodies
were consistently found in clearly recognizable lysosomes
(defined by structures surrounded by a single membrane and
containing moderately osmiophilic, amorphous matrix) (Fig.
5A). They showed a typical pattern with closely apposed layers
at a 5-nm distance. These myeloid bodies tended to disappear
a;a
a# •t$V..it. .j!'I
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Fig. 4. Histological and h,stoautoradio—
graphic evidence of tubular regeneration
and perituhu/ar inflammation after infusion
with the high dose (140 mg/kg; day 2). A A
regenerating tubule, identified by the pres-
ence of epithelial ce/Is with an i/I-developed
brush border and an enlarged nucleus (ar-
row heads). The same tubule also contains
seemingly differentiated cells displaying fully
developed brush border. (Periodic acid
Schiff/H & F) B to E Histoautoradiographs
(following l3H]-thymidine administration in
vivo, see Fig. 3) counterstained with H & E.
B Clusterof labelled nuclei in a regenerating
tul,ule. C Labelled nuclei in an apparently
unaffected tubule; D Labelled cell (flbroblast
or endothelial?) in the interstitiurn without
sign of lvmphocytic irflltration. E
Lvinphocytic infiltration with labelled nuclei.
Bars are 20 tim.
during the observation period by a reduction of their size and a less myeloid bodies were encountered, hut these kept their
teasing of their edges (Fig. 5B). This disappearance of myeloid typical multilamellar, concentric appearance. Animals treated
bodies affected all lysosomes and segregation of lamellar struc- with the medium dose showed an intermediate behavior.
tures in vacuoles ("residual bodies") [32J was not evidenced. At medium and high doses, however, the aggregated volume
Osmiophilic, structureless dots as well as zones with a more of myeloid bodies increased faster than that of lysosomes. since
electron-lucent core were observed alongside with the dis- they occupied up to 35 and 45% of the lysosomal space at day
appearance of myeloid bodies (Fig. 5C). At the high dose, 2, respectively, as compared to 25 and 18% at day 0. Table 1
myeloid bodies became much more abundant from day 0 to day also shows the aggregated volume of electron-lucent vacuoles,
2, most of them stuffing oversized and disformed lysosomes. most commonly observed just below the brush border. The
Part of the myeloid bodies showed a wider apposition pattern of transient increase seen is, however, not dose-dependent and is
the lamellae (Fig. 5D). Occasionally, clumps of myeloid bodies barely significant in view of the large variations noted.
appeared devoid of a limiting membrane (Fig. SE). At day 4, The other subcellular organdies showed no consistent altera-
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10
0
2
4
6
0.65 0.30
0.36 0.17
0.32 0.11
0.28 0.19
3.56 0.45
2.70 0.93
2.68 0.79
2.03 0.61
3.53 0.80
3.32 1.53
2.18 0.99
1.63 0.63
18.2
13.3
11.9
13.7
60
0
2
4
1.67 0.25
1.15 0.l3'
0.62 0.08"
6.58 1.20
3.28 0.34d
2.94 0.52"
2.48 0.50
2.89 0.88
1.74 0.28
25.4
35.1
21.1
140
0
2
4
1.42 1.11
4.06 2.07"
1.70 0.50
7.93 1.59
9.18 2.13
5.62 1.10"
3.32 1.03
2.42 0.71
1.30 0.54
17.9
44.2
30.2
Controls — — 2.05 1.14 2.27 0.65 —
"Photomicrographs, each covering about 350 z2, were taken at random at a final magnification of x 10,000. Six or seven micrographs were taken
at random from each rat for the analysis. Data are presented as mean so of four animals equally treated at each point.
Day 0 corresponds to 2 hr after stopping the gentamicin infusion.
Controls rarely showed lysosornes containing ill-defined dense osmiophilic zones without lamellar pattern.
Significance (P < 0.05) was tested for the percentage of cell volumes occupied by myeloid bodies and lysosomes within each dosage between
day 0 and subsequent days.
tions, except that in some cells no or only poorly developed
brush border was seen at day 2. Occasionally, swollen
mitochondria were also noted at day 4 after the high dose. The
lumen showed clusters of lamellar material, with a wide pattern
(Fig. SF) as from day 2 at the medium and high doses. This
material persisted up to day 4, but because of its focal distribu-
tion, no quantitative assessment was undertaken. It was also
seen at the low dose, albeit, very infrequently.
Discussion
Gentamicin was administered by continuous intravenous
infusion because its pharmacokinetic properties—confirmed in
our system by preliminary experiments [331—have shown that
this mode of administration results in a faster uptake of the drug
by the kidney cortex, as compared to the administration of an
identical amount by single or multiple injections [34—36]. Yet
the serum concentrations were within the clinical range, at least
for the low and medium doses. The pharmacokinetic basis of
our method can be found in the saturable character of the
aminoglycoside association to brush border [12, 371 and uptake
by the kidney cortex ([37, 38]; see [39, 40] for kinetic models of
adsorptive pinocytosis), Actually, the serum concentration
corresponding to half-maximal velocity of uptake (apparent Km)
is 18 g/ml, as found in in vivo experiments [33].
The severity and the evolution of the lysosomal phospho-
lipidosis was clearly dose-related when morphological criteria
were used in a quantitative manner. Sphingomyelinase inhibi-
tion was also clearly dose-dependent, as previously reported for
cultured cells exposed to gentamicin [41]. This enzyme was
used in the present experiments to monitor the changes in
phospholipid breakdown capabilities of lysosomes on gen-
tamicin treatment as previously reported with animals [10, 22,
23, 42] or cultured cells [41]. Recently we also reported that
gentamicin can affect both sphingomyelinase and phospholipase
A1 of the kidney in vivo, so one can reasonably presume that
the intralysosomal catabolism of the major phospholipids could
be impaired (see [10, 20] for discussion).
Total phospholipids showed dose-related changes for the high
and medium doses in relation to the severity of the enzyme
inhibition. At the low dose, no significant excess was detected
although myeloid bodies were present. This is probably due to
the variations seen in controls and to the limited extent of the
phospholipidosis at this dose.
Our approach allowed us to study the recovery from gentami-
cm-induced phospholipidosis in proximal tubules. This re-
covery occurred in all conditions. The underlying mechanisms
may, however, be different at low and high doses, since only the
latter is associated with signs of cellular necrosis and regeneration.
A previous study [27] demonstrated a correlation between the
DNA specific radioactivity and the frequency of labelled nuclei
in rats injected with [3H]-thymidine after gentamicin treatment.
As discussed earlier [271 the increased incorporation of [3H]-
thymidine in proximal tubules is most likely an indication of a
regenerative response to necrosis. Necroses were observed in
the present experiments and have also been reported following
high doses of gentamicin [1—7, 43]. Gentamicin also causes
tubular regeneration [22, 24—26, 44] as do other compounds
injurious to proximal tubules, for example, cis-Platinum [45] or
mercuric chloride [46]. Necroses and shedding of dead cells in
urine would also account for the sharp decline of cortical drug
concentration during the observation period. Such a rapid loss
was also found on discontinuation of therapy with animals
treated 8 days at 50 mg/kg [42] or during the phase of necrosis-
regeneration seen during continuous therapy at 40 mg/kg [261.
The labelling of the interstitium may indicate the onset of a
peritubular inflammation, which is known to be associated with
the acute tubular necrosis induced by gentamicin [47].
In contrast to the results obtained at the high dose, recovery
from the low dose treatment did not appear to involve a
necrosis-regeneration process. Yet, sphingomyelinase activity
Dose
mg/kg
Days after
treatmenV'
Table 1. Morphometrical analysis of myeloid bodies, lysosomes, and vacuoles in proximal tubular cells'
Myeloid bodies (A)
Percentage of cell volume occupied by
Lysosomes (B) Vacuoles (C)
Vol of lysosomes
occupied by
myeloid bodies
A/B x 100
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Fig. 5. Electron microscopic appearance of myelo,d bodies and lysosomes in proximal tubular cells of rat kidney following gentamicin infusion.
A Intralysosomal myeloid bodies 2 hr after the end of the infision with the low dose (10 mg/kg) displaying a regular pattern of closel apposed
layers (inset). (x 17,000 — inset >< 165,000) B Lvsosomes show less clearly defined mveloid bodies 2 days after cessation of the infusion at the low
dose. The lamellar structures show less closely apposed, interrupted lipid layers, a more electron-lucent core and a teasing of their edges. (Arrow,
inset) ( x 17,000 — inset x 165,000) C Osiniophilic structureless dots sometimes with more translucent core 4 days after the low dose. At higher
magnification a layered pattern is no longer present in the osmiophilic structures (arrow, inset). (x 20,000 inset x 165,000) D Enlarged and
disforined lvsosome containing many mveloid bodies 2 days ter the infusion with the big/i dose (140 mg/kg). Some of the myeloid bodies show
a partially more widened apposition pattern of the lamellae (arrow). (x 16,500)
M ni - - -,
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Fig. 5E Cluster of loosely arranged myeloid bodies not surrounded by a limiting membrane, observed 2 days after the high dose. The zone
photographed is away from the lumen (not shown). (x 15.000) F Mveloid bodies wit/i loosely apposed "whorls" (arrow) in the proximal tubular
lumen seen at medium and high dose as twin day 2. These myeloid bodies persisted focally in the lumen of proximal tubules until day 4. They
were also seen at the low dose albeit very infrequently. (x 10,500)
returned to normal values, although we do not know whether
this results from compensatory synthesis of new molecules of
enzyme or a relief of inhibition by the partial elimination of the
aminoglycoside. In parallel, myeloid bodies were almost com-
pletely cleared from all lysosomes of the proximal tubular cells;
true residual bodies 132, 481 were not detected. Thus,
phospholipids were either degraded (as suggested by our images
in Fig. 5) or expelled. The latter mechanism might explain the
presence of lamellar structures in the lumen. Exocytosis [49]
was, however, not unambiguously evidenced in the present
experiments. Yet, we do not know whether the morphological
differences in these myeloid bodies are associated with a
modification of their chemical composition or a change in their
supramolecular organization. Although not entirely ruled out by
our kinetic data, elimination ofgentamicin by mere diffusion out
of the cell is unlikely. The drug is indeed localized in lysosomes
112. 161, where it is fully protonated due to acid pH [50, 51] and
probably bound to acidic phospholipids [10. 52]. Thus, the drug
could slowly leak from lysosomes during the membrane
recycling/shuttle which is associated with endocytosis [53—55]
or be expelled by exocytosis [49].
The present observations may have a number of potential
clinical implications. First, it would call for caution against the
use of infusion because this mode of administration is associ-
ated with the fastest uptake of the aminoglycoside by the
kidney, thus increasing the risk of toxicity. This was already
suggested by other investigators [341. Second. as long as the
cortical concentration of gentamicin does not reach a certain
level (200 sg/g in the rat), regression of the tubular alterations
without necrosis-regeneration is observed. Third. the tissue
drug levels are no longer an index of the severity of the
alterations, when necrosis-regeneration has taken place. Thus.
the determination of these levels, by pharmacokinetic studies
[56] or by postmortem examination may be of limited value
after the first days of therapy.
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